Soluble interleukin-2 receptor [sIL-2R] as a tumor marker in hematologic malignancies
New Egyptian Journal of Medicine [The]. 1997; 16 (4): 352-358
in English
| IMEMR
| ID: emr-46217
ABSTRACT
This work aimed to evaluate serum levels of sIL-2R in some of the hematologic malignancies and to find out if it could be a predictive marker of tumor burden and response to therapy. The mean value of sIL-2R in patients with acute lymphoblastic leukemia [ALL] was significantly higher than the controls. It was also significantly high in the patients with activity as compared with those at remission. Patients with chronic lymphocytic leukemia [CLL] had significantly elevated sIL-2R compared with the controls. The mean value of sIL-2R in the newly diagnosed cases of CLL was significantly higher than that of the group under treatment. There was no significant difference in the mean value of sIL-2R on comparing patients with stage I CLL to those with stage II. There was a significant difference between patients with stage I CLL and those with stage IV and between patients with stage II and stage IV. Newly diagnosed cases had a significantly high mean serum value of sIL-2R compared with those under treatment. Also, patients under treatment showed a significantly high mean serum value of sIL-2R compared with those at remission. Thus, it is clear that measurements of serum sIL-2R in patients with ALL, CLL, non-Hodgkin's lymphoma [NHL] and Hodgkin's lymphoma [HL] could offer a useful marker for tumor burden, prognosis and monitoring of treatment
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Lymphoma, Non-Hodgkin
/
Hodgkin Disease
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Biomarkers, Tumor
/
Interleukin-2
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
New Egypt. J. Med.
Year:
1997
Similar
MEDLINE
...
LILACS
LIS